Antimicrobial peptides : A new alternative for the treatment of aspergillosis
Copyright © 2024 SPLF. Published by Elsevier Masson SAS. All rights reserved..
Aspergillus fumigatus is the predominant fungal species causing pulmonary aspergillosis. The present-day anti-aspergillosis arsenal is limited, with a number of molecules occasioning severe side effects (amphotericin B) or provoking significant drug interactions (azole derivatives). Moreover, the recent emergence of azole-resistant A. fumigatus strains is a cause for concern. In this context, antimicrobial peptides (AMPs) are emerging as a promising therapeutic approach and alternative or complement to conventional antifungals.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Revue des maladies respiratoires - 41(2024), 4 vom: 06. Apr., Seite 283-288 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Peptides antimicrobiens : une nouvelle alternative pour le traitement des aspergilloses |
|---|
| Beteiligte Personen: |
Rochard, C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antifongique |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 15.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rmr.2024.02.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36948598X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36948598X | ||
| 003 | DE-627 | ||
| 005 | 20240415233348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240309s2024 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.rmr.2024.02.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1376.xml |
| 035 | |a (DE-627)NLM36948598X | ||
| 035 | |a (NLM)38458868 | ||
| 035 | |a (PII)S0761-8425(24)00141-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Rochard, C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antimicrobial peptides |b A new alternative for the treatment of aspergillosis |
| 246 | 3 | 3 | |a Peptides antimicrobiens : une nouvelle alternative pour le traitement des aspergilloses |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 SPLF. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Aspergillus fumigatus is the predominant fungal species causing pulmonary aspergillosis. The present-day anti-aspergillosis arsenal is limited, with a number of molecules occasioning severe side effects (amphotericin B) or provoking significant drug interactions (azole derivatives). Moreover, the recent emergence of azole-resistant A. fumigatus strains is a cause for concern. In this context, antimicrobial peptides (AMPs) are emerging as a promising therapeutic approach and alternative or complement to conventional antifungals | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aspergillus fumigatus | |
| 650 | 4 | |a antifongique | |
| 650 | 4 | |a antifungal | |
| 650 | 4 | |a antimicrobial peptide | |
| 650 | 4 | |a aspergillose | |
| 650 | 4 | |a aspergillosis | |
| 650 | 4 | |a peptide antimicrobien | |
| 650 | 7 | |a Antimicrobial Peptides |2 NLM | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 650 | 7 | |a Azoles |2 NLM | |
| 700 | 1 | |a Bigot, J |e verfasserin |4 aut | |
| 700 | 1 | |a Balloy, V |e verfasserin |4 aut | |
| 700 | 1 | |a Hennequin, C |e verfasserin |4 aut | |
| 700 | 1 | |a Guitard, J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue des maladies respiratoires |d 1988 |g 41(2024), 4 vom: 06. Apr., Seite 283-288 |w (DE-627)NLM012622443 |x 1776-2588 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2024 |g number:4 |g day:06 |g month:04 |g pages:283-288 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rmr.2024.02.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2024 |e 4 |b 06 |c 04 |h 283-288 | ||